Fierce Biotech6d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
The Harvard Crimson9d
Biotech Giant Roche Launches Innovation Center on Harvard’s Allston Research Campus
F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...
BioSpace7d
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...
Reuters7d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
The obesity market is not "one size fits all", and Roche is seeking to build a portfolio of weight-loss drugs with different strengths to cater to various needs, including muscle preservation and ...